Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cenobamate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : SK Biopharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
SK Biopharmaceuticals’ epilepsy drug cenobamate OKed in Israel
Details : Dexcel holds exclusive commercialization rights to Xcopri (cenobamate), is an antiseizure medication for epilepsy in Israel.
Product Name : Xcopri
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 03, 2023
Lead Product(s) : Cenobamate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : SK Biopharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Dental and Oral Health
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy and Safety of Chlorhexidine Gluconate Chip (PerioChip®) in Therapy of Peri-implantitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2014
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Dental and Oral Health
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 30, 2010
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lercanidipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Recipient : Meir Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Antihypertensive Efficacy of Fixed Combination Drug
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 29, 2010
Lead Product(s) : Lercanidipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Recipient : Meir Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine
Therapeutic Area : Dental and Oral Health
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2010
Lead Product(s) : Chlorhexidine
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
